Michael Muller, Anna Kantosalo, et al.
CHI 2024
With the advent of deep generative models in computational chemistry, in-silico drug design is undergoing an unprecedented transformation. Although deep learning approaches have shown potential in generating compounds with desired chemical properties, they disregard the cellular environment of target diseases. Bridging systems biology and drug design, we present a reinforcement learning method for de novo molecular design from gene expression profiles. We construct a hybrid Variational Autoencoder that tailors molecules to target-specific transcriptomic profiles, using an anticancer drug sensitivity prediction model (PaccMann) as reward function. Without incorporating information about anticancer drugs, the molecule generation is biased toward compounds with high predicted efficacy against cell lines or cancer types. The generation can be further refined by subsidiary constraints such as toxicity. Our cancer-type-specific candidate drugs are similar to cancer drugs in drug-likeness, synthesizability, and solubility and frequently exhibit the highest structural similarity to compounds with known efficacy against these cancer types.
Michael Muller, Anna Kantosalo, et al.
CHI 2024
Yair Schiff, Vijil Chenthamarakshan, et al.
ICASSP 2022
George Kour, Naama Zwerdling, et al.
NAACL 2025
George Kour, Marcel Zalmanovici, et al.
EMNLP 2023